# Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer

> **NCT00004221** · PHASE2 · TERMINATED · sponsor: **Gynecologic Oncology Group** · enrollment: 12 (actual)

## Conditions studied

- Malignant Ovarian Mixed Epithelial Tumor
- Ovarian Clear Cell Cystadenocarcinoma
- Ovarian Endometrioid Adenocarcinoma
- Ovarian Mucinous Cystadenocarcinoma
- Ovarian Serous Cystadenocarcinoma
- Primary Peritoneal Carcinoma
- Stage III Ovarian Cancer
- Undifferentiated Ovarian Carcinoma

## Interventions

- **DRUG:** Carboplatin
- **DRUG:** Cyclophosphamide
- **BIOLOGICAL:** Filgrastim
- **DRUG:** Paclitaxel
- **PROCEDURE:** Peripheral Blood Stem Cell Transplantation
- **DRUG:** Topotecan Hydrochloride

## Key facts

- **NCT ID:** NCT00004221
- **Lead sponsor:** Gynecologic Oncology Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-11
- **Primary completion:** 2002-02-06
- **Final completion:** —
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2017-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004221, "Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00004221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*